The company said in a news release that it filed the patent request ahead of Phase 2 clinical trials of the formulation. The therapy was developed by MMJ Bioscience, an affiliate of MMJ International Holdings, which is based in Reston, Virginia.
Dr. Bianca Weinstock-Guttman, a neurology professor at the New York State MS Consortium, will oversee the study of the potential therapy’s ability to help patients with progressive MS, the most severe form.
“Entering Phase 2 trials is a highly significant point in the development of our cannabis-based medicines,” MMJ spokesman Michael Sharpe said in the November 2017 announcement. “These trials will allow us to demonstrate efficacy in a limited number of subjects and to establish the necessary dosage regimen and delivery mechanisms to provide the most effective relief to sufferers